Publications by authors named "A Mendoza-Ladd"
Association between acute pancreatitis severity and ABO/Rh blood group.
Medicine (Baltimore)
November 2024
Article Synopsis
- Acute pancreatitis (AP) is a serious inflammatory condition with a high mortality rate, and this study investigates its severity in relation to ABO/Rh blood types.
- A review of 358 hospitalized patients with AP found that 20.9% had non-mild forms, with varying rates across different blood groups, but no significant correlations were discovered.
- The study concluded that blood type does not significantly influence the severity of acute pancreatitis, indicating that other factors are likely critical in the condition's inflammatory response.
Endoscopic ultrasound-guided biopsy via fine-needle biopsy/fine-needle aspiration (FNB/FNA) is currently the standard method to sample tumors in the mediastinum and abdomen. Although specimens obtained with these needles are acceptable, a histological diagnosis is not always possible. Recently, a new EUS-guided core needle biopsy (EUS-CNB) device became available.
View Article and Find Full Text PDFBackground And Aims: The optimal number of passes to maximize the diagnostic ability of EUS fine-needle biopsy (FNB) of solid pancreatic masses (SPMs) is not well known. We conducted a systematic review to evaluate the impact of the incremental number of passes on diagnostic accuracy, tissue adequacy, and diagnostic yield for EUS-FNB of SPMs.
Methods: We searched MEDLINE, Embase, Scopus, and Cochrane Central for randomized controlled trials comparing per-pass diagnostic outcomes of FNB needles in patients with SPMs.
Objectives: Large surface area microparticle paclitaxel (LSAM-PTX) provides an intratumoral (IT) chemotherapeutic depot. Safety, tolerability, and tumor response to IT LSAM-PTX delivered by endoscopic ultrasound-fine needle injection were evaluated in subjects with unresectable locally advanced pancreatic cancer (LAPC).
Methods: Ten subjects treated in a dose escalation phase and 22 additional subjects receiving 2 injections, 4 weeks apart, of 15 mg/mL LSAM-PTX were followed for 12 months.